Conditions: Varicose Veins
Keywords: Varicose Veins
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
To determine the effect and safety of Varisolve® 0.125% \[0.2%\]

Detailed description:
In patients with SFJ incompetence due to reflux of the Great Saphenous Vein (GSV) or major accessory veins, with venous disease manifested by both symptoms and visible varicosities: using duplex ultrasonography, to evaluate the efficacy of Varisolve® 0.125% \[0.2%\] as assessed by the elimination of SFJ reflux and/or occlusion of the treated vein

Arms:
arm 1: None

Interventions: intervention 1: Polidocanol Endovenous Microfoam 0.125%
Intervention descriptions: intervention 1: Polidocanol Endovenous Microfoam 0.125%, single dose

Protocol document: